Physician profile
Daniel Burkholder
NPI 1871153981
$3,701.58
in general payments reported to CMS, 2019-2025
18 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $371 · 2023: $547 · 2024: $1,216 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.78 |
| Education | $151.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,182.51 | 2022-2025 | Rinvoq, Skyrizi |
| Madrigal Pharmaceuticals | $493.38 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $346.91 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $250.59 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $247.08 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $246.40 | 2024 | Stelara, Remicade, Tremfya |
| Amgen INC. | $237.37 | 2023 | Repatha |
| Regeneron Healthcare Solutions, INC. | $221.16 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2024 | Zeposia |
| Pfizer INC. | $102.08 | 2025 | |
| Ardelyx, INC. | $82.20 | 2022-2025 | Ibsrela |
| Celgene Corporation | $34.49 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $34.26 | 2023-2025 | Vegzelma, Yuflyma |
| Alcresta Therapeutics, INC. | $24.48 | 2023 | Relizorb |
| Evoke Pharma, INC. | $23.54 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $18.57 | 2025 | |
| Novo Nordisk INC | $17.87 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $14.29 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Burkholder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.